Diametra, which specialises in the development and commercialisation of manual immunoenzymatic assays, is based in Spello, Umbria, and employs approximately 25 staff.
In the year-ended December 31, 2013, it generated revenues of €3.3m and an EBIT of €0.3m.
The acquisition is in line with the IDS’ strategy of building its presence as a leading solution provider for speciality testing.
In particular, it augments the group’s endocrinology pipeline and provides it with additional development and manufacturing capabilities.
Patrik Dahlen, chief executive of IDS, said: “We are delighted to have secured the acquisition of Diametra, which will assist in the acceleration of our strategic plan outlined earlier this year.
“In particular, Diametra will provide immediate access to endocrinology manual assays in the area of steroid hormones that can be converted to automated assays for our iSYS instrument.
“We continue to pursue complementary acquisitions that will help us grow our specialist endocrinology menu and build operational excellence.”